title: Phase II study of oral ftorafur and uracil in patients with advanced renal cell carcinoma.
authors.forename: E
authors.initials: E
authors.lastname: Esteban
authors.forename: J M
authors.initials: JM
authors.lastname: Buesa
authors.forename: J
authors.initials: J
authors.lastname: Cueva
authors.forename: Y
authors.initials: Y
authors.lastname: Fernández
authors.forename: I
authors.initials: I
authors.lastname: Peláez
authors.forename: J L
authors.initials: JL
authors.lastname: Fernández
authors.forename: A
authors.initials: A
authors.lastname: Sanz
authors.forename: I
authors.initials: I
authors.lastname: Palacio
authors.forename: E
authors.initials: E
authors.lastname: Estrada
authors.forename: J M
authors.initials: JM
authors.lastname: Gracia
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D005641:Tegafur; D014498:Uracil